Feeds:
Posts
Comments

Posts Tagged ‘Plavix’

*****

TODAY’S NEWS

TriCor = placebo? Not good news for Abbott A popular triglyceride-lowering drug that has been taken by millions of Americans failed to prevent heart disease in a big federal study being presented todaymore

FDA to Eli Lilly/Amylin on once-weekly Byetta: No.

OSI to Astellas: No.

FDA to Plavix (from BMS and Sanofi): black-box warning.

RECOMMENDED

Negotiations Training/Presentation Training – Your sales people, account managers, leaders and executives need  to grow in these skills. We’ve got the partners you need in the Impactiviti network. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.

PLUS

You’ve heard all about reach and frequency. How about each and recently? And, when it comes to Pharma and Social Media: One or Many?

JUST FOR FUN

Dogs filmed at 1,000 frames per second. You’ve never seen dogs jump quite like this before.

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Visit the Impactiviti Job Board

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

***

Read Full Post »

TODAY’S NEWS

How to do dumb insider trading – a lesson.

Experimental Plavix competitor Brilinta showing improved efficacy in ACS stent patients.

Enbrel competitor Stelera shows greater efficacy in psoriasis treatment.

Obesity leveling off in U.S., but Diabetes is killing the economy.

RECOMMENDED

Management development. From full curriculum planning to workshops to targeted courses, we have the providers you need in our vendor/partner network. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.

PLUS

Looking to get started in social media, or find out where all the pharma social media resources are? Start here.

JUST FOR FUN

Visual awesomeness, part 2 – another spectacular view of Martian landforms.

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

Connect with Steve Woodruff

Read Full Post »

TODAY’S NEWS

AstraZeneca’s experimental drug may bring serious competition to Plavix – AstraZeneca‘s new pill Brilinta for preventing heart attacks works better than Plavix, the world’s second biggest selling drug, without increasing the amount of life-threatening bleeding, researchers said on Sundaymore

B-I‘s new drug Praxada poised to finally provide an alternative to warfarin – Patients at risk of stroke due to an erratic heartbeat should soon have a viable alternative to 50-year-old warfarin, after a new pill from Boehringer Ingelheim beat expectations in a major clinical studymore Plus, new B-I drug for COPD is looking promising.

Encouraging results for Angiomax in cardiac mortality/survival study – The Medicines Company today announced the publication of one-year results from the landmark HORIZONS-AMI Trial. The trial showed that patients who had suffered the most severe form of heart attack and received angioplasty were significantly less likely to suffer cardiac death and had significantly better overall survival if treated with Angiomax (bivalirudin) compared with those treated with heparin plus a platelet glycoprotein IIb/IIIa inhibitor (GPI)more

FDA to Allos: not so sure about your lymphoma data – Food and Drug Administration reviewers, in a summary prepared for an advisory panel, said their two issues with Allos’ application were “the clinical significance of tumor response and duration of response” as well as “whether the benefit:risk ratio is favorable” for Folotynmore

RECOMMENDED

Technology. Learning Management Systems. On-line assessment. eMarketing. Social Media. If you’re looking for expertise, and/or for vendor connections in the technology sphere, Impactiviti can help. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for information and recommendations!

PLUS

Couldn’t stop myself from including a link to this press release – can you discover what in the world the product being discussed is for? Neither can I…

JUST FOR FUN

Turn up your speakers, sit back for a minute or two, and just enjoy this remarkable video. Rain.

On a personal note: Next week one of my sons joins the Marines. Some thoughts from a proud Dad.

———-

Subscribe to the Impactiviti blog via e-mail

Connect with Steve Woodruff

Read Full Post »

Did you know you can get Impactiviti Daily (Top Pharma News) direct to your Inbox each morning? Just click here to subscribe!

TODAY’S NEWS

Amylin to be led by former Novartis exec – Amylin Pharmaceuticals has taken another step forward in its long & storied history. The company has announced that former Novartis executive Paulo Costa will become its new chairmanmore

An interesting lawsuit: individual suing Celgene for blockbuster drug idea – In 1996, Beth Jacobson was watching her husband, a 35-year-old cardiologist, die from the blood cancer multiple myelomamore

Gene variation impacts 1/3 of Plavix patients? – A common gene variation explains why many people are not helped by the widely prescribed blood thinner Plavix, U.S. researchers said on Tuesday in a study confirming earlier research and paving the way for tests to screen patients before they get the drugmore

From the rumor mill – Glaxo eyeing Human Genome Sciences? And, is B-I cutting a major percentage of its sales force in the U.S.? (can anyone confirm or deny with facts?)

RECOMMENDED

Corporate HR workshops – Sexual Harassment. Compliance. Communications. Ethics. Diversity. The Impactiviti Partner Network has what you need. Contact me (stevew at impactiviti dot com, or phone at 973-947-7429) for information and recommendations!

PLUS

Are placebos getting more effective? What’s going on here? – From 2001 to 2006, the percentage of new products cut from development after Phase II clinical trials, when drugs are first tested against placebo, rose by 20 percent. The failure rate in more extensive Phase III trials increased by 11 percent, mainly due to surprisingly poor showings against placebomore

JUST FOR FUN

Who’s got the better colors? An eye-popping series of 3 photos you’ll enjoy!

———-

Subscribe to the Impactiviti blog via e-mail

Connect with Steve Woodruff

Read Full Post »

This will probably be the last Top Three post for about a week or so, as I head out to Chicago for the SPBT (Society of Pharmaceutical and Biotech Trainers) conference. And there’s a bit of backlog today, so here goes – more than three!

Acorda shares jump after its experimental MS pill gets a priority review notice from FDA. Oral MS treatments are going to be big news over the next year…

Vanda gets approval for its schizophrenia drug. And, as is typical of atypicals, a black box warning.

Roche‘s Avastin cleared for brain cancer.

Solvay receives FDA approval for pancreas drug Creon.

Drug-coated stents – safety verified, and better at keeping arteries open.

Plavix and Purple don’t mix?

An interesting discussion of marketing tactics (pay-for-non-performance) in Europe over osteo drugs, and the upcoming Novartis/Amgen tussle in that area.

Credibility on the commercial side of pharma marketing (Vioxx): Not. Not.

——

Subscribe to the Impactiviti blog via e-mail

Subscribe to the Impactiviti blog via RSS

Connect with Steve Woodruff


Read Full Post »

From today’s Wall Street Journal (subscription may be required)

Over the next few years, the pharmaceutical business will hit a wall.

Some of the top-selling drugs in industry history will become history as patent protections expire, allowing generics to rush in at much-lower prices. Generic competition is expected to wipe $67 billion from top companies’ annual U.S. sales between 2007 and 2012 as more than three dozen drugs lose patent protection. That is roughly half of the companies’ combined 2007 U.S. sales.

At the same time, the industry’s science engine has stalled. The century-old approach of finding chemicals to treat diseases is producing fewer and fewer drugs. Especially lacking are new blockbusters to replace old ones like Lipitor, Plavix and Zyprexa.

The coming sales decline may signal the end of a once-revered way of doing business. “I think the industry is doomed if we don’t change,” says Sidney Taurel, chairman of Eli Lilly & Co. Just yesterday, Bristol-Myers Squibb Co. announced plans to cut 10% of its work force, or about 4,300 jobs, and close or sell about half of its 27 manufacturing plants by 2010…more

(the article goes on to explain the threat of patent expirations, the dearth of great pipeline drug candidates, etc.

In a related note to the last paragraph above, the Bristol-Myers press release regarding their re-org/right-sizing is an absolute classic of biz speak. The link to the full article, which is really almost a self-parody, is here…below are a few choice quotes:

(Headline): Bristol-Myers Squibb Company Outlines Strategy and Productivity Transformation Initiative During Update to Investment Community (always tremble when you read words like this – it inevitably means layoffs!)

The company is seeking opportunities to maximize the value of its Health Care Group companies for shareholders. Consistent with this objective, the company plans to divest its Medical Imaging business. Further, the company is currently reviewing a range of strategic alternatives for its ConvaTec and Mead Johnson businesses. “We remain fully aware of the important contributions these businesses have made to earnings and cash flow, and we will take these factors into full consideration when weighing our strategic options,” said James M. Cornelius, chief executive officer, Bristol-Myers Squibb…

In addition to its overview of the company’s strategy, senior management will discuss the scope and details of its Productivity Transformation Initiative, the company’s first step to achieve a culture of continuous improvement which was begun earlier this year. Over 300 initiatives have been identified that will enhance the company’s efficiency, effectiveness and competitiveness and substantially improve its cost base….

Some positions have been eliminated in 2007 and the substantial majority of positions will be eliminated in 2008 and 2009. “It is difficult to see our valued colleagues leave the company, but right-sizing our workforce across all areas is critical to achieving our productivity goals and enhancing the competitive position of the company. While we are reducing headcount in certain functions, we will continue to invest in R&D, biologics and commercialization talent,” said Mr. Cornelius…

…and, the best sentence of all: Key productivity initiatives include reducing general and administrative operations by simplifying, standardizing and outsourcing, where appropriate, processes and services, rationalizing the company’s mature brands portfolio, consolidating its global manufacturing network while eliminating complexity and enhancing profitability, simplifying its geographic footprint and implementing a more efficient go-to-market model.

Read Full Post »